Lecanemab is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. It is available as injection for intravenous and subcutaneous use. MedsAcross supplies Lecanemab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. LEQEMBI is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease.
Source: US FDA prescribing information
Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. LEQEMBI reduces amyloid beta plaques, as evaluated in Study 1 and Study 2.
Source: US FDA prescribing information
Confirm the presence of amyloid beta pathology prior to initiating treatment. Obtain a recent baseline brain MRI prior to initiating treatment. Obtain an MRI after 1, 2, 3, and 6 months of treatment. If radiographically observed ARIA occurs, treatment recommendations are based on type, severity, and presence of symptoms. Recommended starting dosage: Intravenous infusion: 10 mg/kg once every 2 weeks administered after dilution as an intravenous infusion over approximately one hour. Subcutaneous injection: 500 mg administered once a week using the LEQEMBI IQLIK autoinjector. After 18 months, continue treatment with the starting dosage or transition to an intravenous or subcutaneous maintenance dosage. Recommended maintenance dosage: Intravenous infusion: 10 mg/kg once every 4 weeks. Subcutaneous injection: 360 mg administered once a week using the LEQEMBI IQLIK autoinjector.
Source: US FDA prescribing information
LEQEMBI is contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. Reactions have included angioedema and anaphylaxis.
Source: US FDA prescribing information
Boxed warning (amyloid related imaging abnormalities): Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment with LEQEMBI. Risk of ARIA, including symptomatic ARIA, was increased in apolipoprotein E ε4 homozygotes compared to heterozygotes and noncarriers. The risk of ARIA-E and ARIA-H is increased in patients with pretreatment microhemorrhages and/or superficial siderosis. If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including MRI scanning if indicated.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Amyloid Related Imaging Abnormalities Hypersensitivity Reactions Infusion-Related Reactions Most common adverse reactions (at approximately 10% and higher incidence compared to placebo): infusion-related reactions, amyloid related imaging abnormality-microhemorrhages, amyloid related imaging abnormality-edema/effusion, and headache. Additionally, injection-related reactions occurred in patients receiving subcutaneously administered LEQEMBI.
Source: US FDA prescribing information
Store LEQEMBI vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Subcutaneous Injection Store LEQEMBI IQLIK autoinjectors in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. If needed, the autoinjectors can be stored at room temperature up to 25°C (77°F) in the original carton for up to 14 days. Once the autoinjector has been stored at room temperature, do not return it to the refrigerator. Store in the original carton to protect from light. Diluted Solution For storage of the diluted infusion solution, see Dosage and Administration. Store in original carton to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Lecanemab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Lecanemab Autoinjector 250 mg/1.25 mL injectionSubcutaneous Cold chain | Eisai | US FDA | Available on request |
| Lecanemab Autoinjector 360 mg/1.8 mL injectionSubcutaneous Cold chain | Eisai | US FDA | Available on request |
| Leqembi 200 mg/2 mL injectionIntravenous Cold chain | Eisai | US FDA | Available on request |
| Leqembi 500 mg/5 mL injectionIntravenous Cold chain | Eisai | US FDA | Available on request |
2 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 4 presentations of Lecanemab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Lecanemab, including Lecanemab Autoinjector, Leqembi.
Yes. The US FDA first approved Lecanemab on 6 January 2023, according to Drugs@FDA.
Yes. Lecanemab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Lecanemab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Lecanemab is classified under ATC code N06DX04 (Lecanemab).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.